Pro Medicus Surges 3% on $29M US Contracts: Buy the Dip or Sell Into Strength at 200x Earnings?

Pro Medicus (ASX: PME) jumped 3% this morning to $258.50 after announcing $29 million in new US contracts spanning three major healthcare providers: Children’s Alabama, Roswell Park Cancer Centre in New York, and Vancouver Clinic in Washington State. For investors watching the medical imaging space, this marks the company’s third major contract announcement in just four months of FY26, tripling the pace from the same period last year, when only one comparable deal was secured. The question now is whether this momentum justifies the stock’s premium valuation or if the 25% pullback from July’s $336 peak presents a better entry point.

What are the Best Healthcare Stocks to invest in right now?

Check our buy/sell tips

Contract Velocity Accelerates as US Healthcare Demand Intensifies

What makes today’s announcement particularly significant is the momentum behind it. Pro Medicus has now secured $273 million in total contract value during the first half of FY26, a pace that suggests the company’s growth trajectory remains intact despite recent share price volatility. This acceleration matters because Pro Medicus’s valuation hinges on sustained contract wins, and the evidence points to strengthening demand rather than a plateau.

The three new clients span different healthcare segments, demonstrating broad market appeal:

• Children’s Alabama – The state’s largest pediatric hospital system, serving 350,000 patients annually, representing the pediatric imaging market
• Roswell Park Cancer Centre – New York oncology specialist, where diagnostic precision and speed are critical for patient outcomes
• Vancouver Clinic – Washington State multi-speciality provider serving the primary care and regional healthcare segment

This diversification reduces concentration risk and suggests the company is winning on technical merit rather than competing solely on price. Hospitals rarely switch imaging platforms lightly; these typically represent 5-7 year commitments worth millions in recurring revenue, providing unusual visibility into future earnings.

The Valuation Debate: Premium Justified or Stretched?

Here’s where it gets interesting for investors. Pro Medicus trades at approximately 200 times forward earnings despite forecasting 38% EPS growth for FY26. The stock has already pulled back 25% from its July peak above $330, yet still carries one of the richest valuations on the ASX.

The bull case rests on quality metrics that few companies can match:

• 90% recurring revenue from long-term hospital contracts spanning 7-10 years
• 85%+ gross margins characteristic of best-in-class SaaS businesses
• Zero debt with $211 million in cash, enabling deal pursuit without dilution
• 100% customer retention since 2009, demonstrating high switching costs

However, the market is clearly pricing in near-perfect execution. At current levels, any slowdown in contract wins or broader tech sector rotation could pressure shares further, as the valuation leaves minimal room for disappointment.

The Investor’s Takeaway

The upcoming RSNA conference in late November could provide the next catalyst, as Pro Medicus has historically used this industry event to announce major contracts. If the company delivers another significant deal at RSNA, today’s rally could extend further.

For growth investors with a 3-5 year horizon, Pro Medicus remains one of Australia’s highest-quality growth stories. The accelerating contract pace suggests market share is being captured from legacy providers, and the recurring revenue model should deliver predictable cash flows as contracts mature. Current holders comfortable with volatility should maintain positions given the fundamental momentum.

However, value-conscious investors should recognise the risk embedded in a 200x earnings multiple. If contract momentum slows, the valuation could compress quickly. Conservative investors might wait for further consolidation below $240 before establishing positions, while those seeking exposure could consider gradual accumulation during pullbacks rather than lump-sum buying at today’s levels.